EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DMF, an activator of Nrf2, could mitigate cholic-acid-induced liver damage in high-fat diet

Diana Abu-Halaka, Einat Rauchbach, Haim Zeigerman, Oren Tirosh

Exploration of Digestive Diseases · 2025

DOI: 10.37349/edd.2025.100581 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Exploration of Digestive Diseases, 2025. Verfasst von Diana Abu-Halaka und 3 weiteren Autor:innen. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a widespread chronic liver condition associated with liver inflammation, fibrosis, and various metabolic disorders. Although cholic acid (CA), a primary bile acid (BA), is known to reduce steatosis when added to a high-fat diet, it may exacerbate hepatocellular injury by promoting oxidative stress and inflammation. Therefore, regulating BA-induced liver toxicity is crucial. Dimethyl fumarate (DMF) is an FDA-approved drug known to activate the nuclear factor erythroid 2 (NFE2)-related factor 2 (Nrf2), a transcription factor that induces cytoprotective genes involved in cellular stress. The present study aimed to investigate whether DMF supplementation could attenuate CA-induced liver injury in high-fat diet-fed mice.

Methods

To induce liver injury, high-fat diet with and without CA were compared for liver damage and liver fat gain. Following the establishment of the toxic but antisteatotic effect of CA, C57BL/6j mice were fed a high-fat diet supplemented with 0.5% CA (HFDCA) with or without DMF (0.3 mg/mL or 0.6 mg/mL), which was administered via drinking water for 7 weeks.

Results

CA was found to be an accelerator of high-fat diet to induce liver damage, but prevented liver fat accumulation. HFDCA mice showed signs of liver damage, including elevated liver enzymes and liver enlargement. However, DMF treatment activated the Nrf2 pathway and partially mitigated the hepatotoxic effect of CA/high-fat diet, although some doses exhibited pro-oxidant effects.

Conclusions

The findings suggest that DMF, as an activator of Nrf2, has potential as a therapeutic agent for liver diseases related to high-fat diets and BA-induced injury, though careful dosage management is crucial to maximize its benefits and mitigate BA toxicity.

Zitieren

APA

Abu-Halaka, D., Rauchbach, E., Zeigerman, H., & Tirosh, O. (2025). DMF, an activator of Nrf2, could mitigate cholic-acid-induced liver damage in high-fat diet. Exploration of Digestive Diseases. https://doi.org/10.37349/edd.2025.100581

Vancouver

Abu-Halaka D, Rauchbach E, Zeigerman H, Tirosh O. DMF, an activator of Nrf2, could mitigate cholic-acid-induced liver damage in high-fat diet. Exploration of Digestive Diseases. 2025. doi:10.37349/edd.2025.100581

BibTeX
@article{AbuHalaka2025,
  author = {Abu-Halaka, Diana and Rauchbach, Einat and Zeigerman, Haim and Tirosh, Oren},
  title = {DMF, an activator of Nrf2, could mitigate cholic-acid-induced liver damage in high-fat diet},
  journal = {Exploration of Digestive Diseases},
  year = {2025},
  doi = {10.37349/edd.2025.100581}
}
Kostenlos starten →